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Abstract
This study determined the depletion pattern of praziquantel (PZQ) from gilthead sea bream (Sparus aurata) muscle plus skin 
tissue. Fish averaging 100.2 ± 17.7 g and kept at 25oC received a PZQ-dosing of 150 mg/kg fish for 3 days. Muscle plus skin tissue 
of ten fish were sampled on days 1, 2, 3, 4, and 6 days post-treatment. Depletion of PZQ from edible gilthead sea bream tissues 
was rapid, as PZQ concentrations decreased to 0.04 μg/g as early as 24 h post-treatment, while it was undetectable at 72 h. This 
information confirms the fact that PZQ is depleted fast from farmed animals, including fish such as the gilthead sea bream, and its 
levels in edible tissues fell below the detection limit in approximately 75 dd.
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Introduction
Praziquantel (PZQ) is a synthetic drug that has re-
ceived early approval as human medicine (Andrews et 
al., 1983). It is effective against a broad range of inter-
nal and external human and animal parasites (Eom et al., 
1988), but registration as a fish medicine is limited. The 
compound affects the integumental parasitic membrane 
by disrupting regulatory processes and inducing spastic 
muscular paralysis (Staudt et al., 1992). 
A wide and comprehensive review of dietary admin-
istered PZQ to control platyhelminth parasites of fish has 
been published recently (Bader et al., 2019). Praziquan-
tel has been proven to be a very effective antiparasitic 
against monogeneans (Hirazawa et al., 2004; Sharp et al., 
2004) and digeneans of fish (Bader et al., 2019). Thus, 
being a promising dietary fish anthelmintic, PZQ is an 
alternative to bath-administered formalin, which current-
ly seems to be the only compound registered to confront 
fish parasites in most European countries, the United 
States, and elsewhere. PZQ could be used in aquaculture 
as a non-registered fish therapeutic method, within the 
‘off-label’ framework described as the cascade princi-
ple (Council Directive 90/676/EEC, Directive 2001/82/
EC, Commission Regulation 37/2010). In such cases, a 
standard withdrawal time (WT) of 500 dd is imposed to 
ensure consumer safety, although a maximum residue 
level (MRL) has not been established for farmed animals 
(EMEA, 1988). Information on the kinetic profile of the 
therapeutics in targeted organisms during and post-treat-
ment is useful for adjusting recommended dosing regi-
mens and estimating withdrawal from the body of treated 
animals. 
While the withdrawal profile of PZQ has been stud-
ied in some farmed fish species including rockfish (Se-
bastes schlegeli) (Kim et al., 2001; 2003), rice field eel 
(Monopterus albus) (Xu et al., 2006) and rainbow trout 
(Oncorhynchus mykiss) (Björklund & Bylund 1987; 
Soukupova-Markova et al., 2016), limited information 
exists for gilthead sea bream (Sparus aurata) (Baralla et 
al., 2020), an important commercialized Mediterranean 
farmed finfish species. Gilthead sea bream suffers from 
severe gill infections due to the monogenean Sparicotyle 
chrysophrii (Sitjà-Bobadilla et al., 2010) and PZQ could 
potentially be used to combat this ectoparasite, provided 
that a rapid removal from the fish body compartment will 
be beneficial for its use as aquatic medicine. The aim of 
this study was to determine the depletion profile of di-
etary administered PZQ in gilthead sea bream following 
multiple dosing administration. The results can be used to 
determine the appropriate withdrawal time in PZQ-treat-
ed fish and evaluate the enforced cascade principle wher-
ever the compound is not registered.
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Materials and Methods
Experimental fish
Two hundred clinically healthy S. aurata averaging 
100.2 ± 17.7 g were obtained from a local fish farm. One 
hundred fish were distributed in 1 m3 cages, located with-
in a 50 m3 cement tank. Water was supplied by open flow 
and oxygen was provided continuously by bubbling air. 
Water temperature and salinity were 25oC and 38‰, re-
spectively. The fish were allowed to acclimate prior to 
experimentation and fed a drug-free commercial diet at 
2% B.W. Management of experimental animals followed 
EU legislation “on the protection of animals used for sci-
entific purposes”, according to Directive 2010/63/EU of 
the European Parliament and of the Council (EU, 2010).
Medicated feed and drug administration
Fish received a commercial feed (BioMar, Denmark) 
(Τable 1) with oil-coated PZQ (Bayer Ltd.), aiming to 
simulate an in situ preparation of a medicated diet. One 
batch of experimental diet was prepared by mixing ap-
propriate amounts of feed, PZQ (1 kg of the diet with 7.5 
g active PZQ), and 100 mL fish oil for several minutes. 
During the trial, the experimental diet was stored at 4oC 
and was left to reach ambient temperature before deliv-
ery. The fish were fed the medicated diet by hand once 
per day for 3 consecutive days at a daily rate of 2% B.W, 
thus aiming for a dose of 150 mg/kg fish per day.
Sampling
Fish sampling was performed at predetermined time 
points post-treatment. The fish was anaesthetized with 
clove oil (40 ppm) and then killed by a blow on the head 
before taking tissue samples. Muscle plus skin tissue 
(approximately 5 g) was obtained from the anterior dor-
sal region of ten fish collected on days 1, 2, 3, 4, and 6 
post-treatment. All prepared tissue samples were imme-
diately frozen and stored at -20°C until analysis.
Chemicals and reagents
Praziquantel analytical standard was obtained from 
Sigma-Aldrich (USA). High performance liquid chroma-
tography (HPLC) grade ethyl acetate, hexane, acetone, 
diethyl ether, and HPLC gradient grade acetonitrile were 
purchased from Fisher Scientific (USA). Other solvents 
and reagents of analytical grade were supplied by Fisher 
Scientific (USA), while heparin (5000 U.I/mL) was ob-
tained from Merck KGaA (Germany). The stock solution 
of 100 μg/mL PZQ was prepared by dissolving PZQ in 
acetonitrile and it was stored at -20°C, while the work-
ing solution (10 μg/mL) was prepared before use with 
acetonitrile:water (35:65 v/v). The working solution was 
further diluted with acetonitrile:water (35:65 v/v) for the 
calibration curve.
Sample preparation
Muscle plus skin tissue samples of S. aurata were pre-
pared according to Tubbs & Tingle (2006). Briefly, tis-
sue sample was sheared, and subsequently 1 g of ground 
sample was placed in a 50 mL centrifuge tube. Six mL 
of ethyl acetate were added and the mixture was homog-
enized with an IKA Ultra-Turrax T25 Disperser (IKA®-
Werke GmbH & Co. KG, Staufen, Germany) for 30 s 
at 16,000 rpm/min. The mixture was shaken for 10 min 
and then centrifuged at 10,000 g for 10 min at 10°C. The 
supernatant was transferred to a 15 mL tube and liquid 
extraction was repeated with 4 mL ethyl acetate before 
being subjected to vortex mixing. The combined extract 
(10 mL) was then evaporated to dryness at 45°C under a 
nitrogen stream. The dried residue was resuspended in 5 
mL hexane and loaded onto an activated silica column 
(Isolute 500 mg SI-IST, UK), which was rinsed with 5 
mL of 15% v/v diethyl ether-hexane where drug elution 
was performed with 5 mL 70% acetone in hexane. Final-
ly, the solvent was evaporated to dryness at 45°C under a 
nitrogen stream and the dry residue was reconstituted by 
1 mL of mobile phase solution, filtered using 0.22 μm ny-
lon filter and injected (200 μL) into the HPLC apparatus.
Chromatographic conditions
Chromatographic separation of PZQ was carried out 
in an HPLC apparatus combining a Waters 600 Pump 
and a 600 Pump system Controller (Milford, MA, USA, 
a Waters 717 Plus Autosampler (Milford, MA, USA) set 
at 10°C injection temperature, a 150 mm × 4.6 mm Lu-
na-C18 column packed with 5 μm particle size equipped 
with a 4mm × 3.0 mm C18 security guard cartridge (both 
from Phenomenex, USA), a 2487 UV detector set at 210 
and Empower Chromatography Software (both from Wa-
ters, Milford, MA, USA). An isocratic mixture of 35:65 
v/v acetonitrile:water was used as a mobile phase. The 
flow rate was constantly maintained at 1.0 mL/min, col-
umn temperature was maintained at 30°C, and was rinsed 
for 20 min with 100% acetonitrile between injections. 
The retention time of PZQ was 18.9 min. 
Table 1. Composition of the experimental diet.
Proximate  
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Calibration curves and recovery rates
To establish the calibration curves for quantification 
of PZQ concentration in muscle plus skin tissue samples, 
PZQ standards were spiked into blank S. aurata tissues at 
final concentrations of 0.01, 0.05, 0.1, 0.25, 0.5 1, 2.5, 5, 
10 μg/g. To determine the drug from the spiked samples, 
the extraction procedure and HPLC method described 
above were used. To evaluate the recovery rates of PZQ 
and the intra- and inter-day Relative standard deviation 
(RSD), three replicates of spiked samples containing 
different concentrations of the substances (0.25-5 μg/g) 
were examined for two days. For quantification, the peak 
area measurements were used. The limits of quantifica-
tion (LOQ) were set to 0.04 μg/g in muscle plus skin. The 
recovery of the method was calculated by comparing the 
determined concentration of spiked samples with those 
of standard solutions (Table 2). The limits of detection 
(LOD) and the limits of quantification (LOQ) were esti-
mated to be 3.3*σ/S and 10*σ/S, respectively (σ = stan-
dard deviation of the y-intercept of the regression line; S 
= slope of the calibration curve) and indicate good sensi-
tivity of the method.
Results and Discussion
The calculated calibration curves presented herein 
reflect a successful linear relationship for PZQ over the 
range of 0.01-10 μg/mL for S. aurata muscle plus skin with 
coefficients of correlation greater than 0.999. The average 
recovery rates of PZQ were estimated to be 84.5% in the 
spike tissues, an indication that the analytical protocol used 
for PZQ detection was also sufficient. Previously, the re-
coveries of PZQ in muscle were estimated to be 100% in S. 
aurata (Baralla et al., 2020), 79- 100% in O. mykiss (Rogs-
tad et al., 1987; Hormazábal & Yndestad, 1995), 82.7% in 
S. schlegeli (Kim et al., 2001), 93- 100% in M. albus (Xu 
et al., 2016) and 95.2% in Pacific bluefin tuna (Thunnus 
orientalis) (Ishimaru et al., 2013).
Measured PZQ concentrations in muscle plus skin sam-
ples of gilthead sea bream fed a PZQ-dosing of 150 mg/
kg for 3 days are presented in Table 3. Depletion of PZQ 
from muscle plus skin was very rapid in the tested fish, 
given that concentrations decreased to 0.04 μg/g as ear-
ly as 24 h post-treatment, while they were not detectable 
after 72 h. This information confirms the fact that PZQ is 
rapidly removed and does not accumulate in farmed ani-
mals (EMEA, 1998), including fish such as S. aurata. Im-
portantly, the drug was undetectable 3 days after treatment 
completion at 25oC or in approximately 75 dd.
In other farmed fish species, removal of PZQ has also 
exhibited a rapid profile. Specifically, in O. mykiss kept at 
10.5oC and administered a single dose of 50 mg/kg fish, 
using, the compound was not detectable in muscle at al-
most 224 dd (Soukupova-Markova et al., 2016). Earlier, 
in O. mykiss kept at 12 or 18oC and force-administered a 
PZQ-dosing of 500 mg/kg fish (tube), it was demonstrat-
ed that PZQ in muscle among other tissues, decreased 
rapidly at both temperatures tested. In particular, 32 h 
after administration, 67-96% of the maximum quantities 
had been excreted (Björklund & Bylund, 1987). In M. 
albus fed 10 mg PZQ/kg fish for 3 consecutive days at 
22°C, PZQ was not detected on the 3rd and 4th day after 
completion of the treatment in muscle and skin, respec-
tively (Xu et al., 2006). Comparably, in S. schlegeli kept 
at 19 - 20°C and fed 200 mg/kg fish for 3 days, PZQ was 
detectable in muscle and skin tissue until 1 and 3 days 
post-treatment, respectively (Kim et al., 2003). In the 
same study, a higher dose of 400 mg/kg fish caused a de-
lay in PZQ removal from the analyzed tissues; drug con-
centrations in muscle or skin 5 and 6 days after therapy 
were measured. Lastly, in T. orientalis following a single 
dietary administration of 15 mg PZQ/kg fish, PZQ was 
undetectable after 24 h in all examined tissues including 
muscle (Ishimaru et al., 2013).
Concerning PZQ excretion, it has been suggested that 
Table 2. Recovery rate and RSD (%) of PZQ in spiked gilthead sea bream muscle plus skin samples (n=3).
PZQ added (μg/g) Recovery (%) Intra-day RSD (%) Inter-day RSD (%)
0.25 98.5 ± 1.9 2.0 1.9
0.5 78.1 ± 1.7 2.1 3.3
1 82.8 ± 2.2 2.6 2.7
5 78.6 ± 1.3 1.7 2.4
Average 84.5
Table 3. Muscle plus skin concentrations of PZQ in gilthead 
sea bream receiving a dose of 150 mg/kg/day for 3 consecutive 
days at 25°C (mean ± st.dev.), n=10.
Sampling time (days after 
treatment)
Muscle (μg/g)
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PZQ is mainly excreted with bile and partly through the 
kidneys since large amounts of the drug were found in 
the bile fluid and hind kidneys of O. mykiss (Björklund 
& Bylund, 1987). However, the physiological differences 
among fresh and marine fish should be taken into consid-
eration in drug excretion. PZQ is also subjected to meta-
bolic processes in fish and appears to be metabolized into 
hydroxylated derivatives in kingfish (Seriola lalandi) 
(Tubbs et al., 2008). The factors affecting the metabolism 
of PZQ in fish such as S. aurata require further investiga-
tion although the estimated parent PZQ concentration in 
edible S. aurata tissues will not be affected.
In conclusion, available data on the removal of PZQ 
from edible fish tissues signifies that PZQ can be used 
safely in S. aurata. The anthelmintic efficacy of PZQ 
against gill parasites of S. aurata, a subject of parallel 
investigation at the Institute of Marine Biology, Biotech-
nology and Aquaculture, will provide added value to the 
results presented herein.
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